- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01414426
Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions
Randomized Placebo- Controlled Pilot Study of ZD6474 as a Chemopreventive Agent for Premalignant Lesions of the Head and Neck
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVE:
I. Determine the effect of ZD6474 (vandetanib) compared to placebo on microvessel density (MVD) from baseline to 3 months in patients at risk for oral squamous cell carcinoma (OSCC) with preneoplastic lesions.
SECONDARY OBJECTIVES:
I. Change in MVD over 6 months. II. Change in putative targets of ZD6474: tissues will be analyzed by immunohistochemistry (IHC) for phosphorylated epidermal growth factor receptor (pEGFR), EGFR, phosphorylated-vascular endothelial growth factor receptor 2 (pVEGFR2), VEGFR2.
III. Change in proliferative index as measured by Ki-67 IHC. IV. Safety, tolerability, and adherence to ZD6474 for 6 months in patients at risk for OSCC.
TERTIARY OBJECTIVES:
I. Compare OSCC incidence in both study arms (ZD6474 and placebo).
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive vandetanib orally (PO) once daily (QD) for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive placebo PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 9 and 12 months and then every 6 months for 2 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histological/cytological confirmation of oral cavity dysplasia and one of three additional criteria:
- Prior history of OSCC
- Loss of heterozygosity (LOH) at 3p or 9p
- Expression by immunohistochemistry (IHC) of budding uninhibited by benzimidazoles 3 (BUB3)/sex determining region Y (SOX4)
- Provision of informed consent
- Females of child bearing age must have a negative serum pregnancy test within 7 days of first dose of study drug
- Patients must not have been taking steroids or are on a stable dose of steroids for at least 14 days before enrollment
- Patients must have a Karnofsky Performance Score of 70% or above
Exclusion Criteria:
- History of malignancy within the last 5 years other than squamous cell carcinoma of the head and neck (SCCHN) and superficial non-melanoma skin cancer; patients with a history of SCCHN must be free of active carcinoma
- Currently receiving treatment for any malignancy
- Serum bilirubin > 1.5x the upper limit of reference range (ULRR)
- Creatinine clearance =< 30 mL/minute (calculated by Cockcroft-Gault formula)
- Potassium, < 4.0 mmol/L despite supplementation; or above the Common Terminology Criteria for Adverse Events (CTCAE) grade 1 upper limit
- Magnesium below the normal range despite supplementation, or above the CTCAE grade 1 upper limit
- Serum calcium above the CTCAE grade 1 upper limit; in cases where the serum calcium is below the normal range, 2 options would be available: 1) the calcium adjusted for albumin is to be obtained and substituted for the measured serum value; exclusion is to then be based on the adjusted for albumin values falling below the normal limit; 2) Determine the ionized calcium levels; if these ionized calcium levels are out of normal range despite supplementation, then the patient must be excluded
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 × ULRR
- Alkaline phosphatase (ALP) > 2.5 x ULRR
- Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the Investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol
- Clinically significant cardiovascular event (e.g. myocardial infarction, superior vena cava syndrome [SVC], New York Heart Association [NYHA] classification of heart disease > 2 within 3 months before entry; or presence of cardiac disease that, in the opinion of the Investigator, increases the risk of ventricular arrhythmia
- History of arrhythmia (multifocal premature ventricular contractions (PVCs), bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation), which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia; atrial fibrillation, controlled on medication is not excluded
- QTc prolongation with other medications that required discontinuation of that medication
- Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age
- Presence of left bundle branch block (LBBB)
- QTc with Bazett's correction that is unmeasurable or ≥450 msec on screening electrocardiogram (ECG); (Note: If a subject has a QTc interval >= 450 msec on screening ECG, the screen ECG may be repeated twice [at least 24 hours apart]; the average QTc from the three screening ECGs must be < 450 msec in order for the subject to be eligible for the study)
- Any concurrent medication with a known risk of inducing Torsades de Pointes, that in the investigator's opinion cannot be discontinued
- Concomitant medications that are potent inducers (rifampicin, rifabutin, phenytoin, carbamazepine, phenobarbital and St. John's Wort) of Cytochrome P450 3A4 (CYP3A4) function
- Hypertension not controlled by medical therapy (systolic blood pressure greater than 160 mm mercury (Hg) or diastolic blood pressure greater than 100 mm Hg)
- Currently active diarrhea that may affect the ability of the patient to absorb the ZD6474 or tolerate diarrhea
- Women who are currently pregnant or breast-feeding
- Receipt of any investigational agents within 30 days prior to commencing study treatment
- Previous enrollment or randomization of treatment in the present study
- Major surgery within 4 weeks or incompletely healed surgical incision before starting study therapy
- Involvement in the planning and conduct of the study (applies to both Astra Zeneca staff and staff at the study site)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I (chemoprevention)
Patients receive vandetanib PO QD for 6 months.
Treatment continues in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Correlative studies
Other Names:
Correlative studies
Other Names:
Correlative studies
Other Names:
Given PO
Other Names:
|
Placebo Comparator: Arm II (placebo)
Patients receive placebo PO QD for 6 months.
Treatment continues in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Correlative studies
Other Names:
Correlative studies
Other Names:
Correlative studies
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison Between Treatment Groups of the Within-patient Change in MVD Score Following Treatment Initiation
Time Frame: Baseline to 3 months
|
A Wilcoxon ranksum test may be used if the normality assumption is not satisfied.
Alternatively, change in MVD may be transformed (e.g.
log-transformation) to satisfy the normality assumption.
Additional analyses will include linear regression models with treatment effect and other prognostic factors as covariates.
|
Baseline to 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Adverse Events
Time Frame: Weekly during treatment, up to week 24
|
Adverse events rate shows the total number of subjects with an AE.
|
Weekly during treatment, up to week 24
|
Number of Participants Who Adhered to Treatment
Time Frame: Over 6 months
|
Number of participants who Adhered to Treatment
|
Over 6 months
|
Development of Oral and Other Cancers
Time Frame: At 6, 9, and 12 months and then ever 6 months for 2 years
|
Number of patients with new cancer
|
At 6, 9, and 12 months and then ever 6 months for 2 years
|
Biologic Effect of EGFR and VEGFR2 Inhibition
Time Frame: Baseline and 3 and 6 months
|
Effect of treatment on EGFR and VEGFR2 inhibition
|
Baseline and 3 and 6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Tanguy Seiwert, M.D., University of Chicago
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 11-0265
- NCI-2011-01246 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Precancerous Condition
-
Xiyuan Hospital of China Academy of Chinese Medical...Guangdong Provincial Hospital of Traditional Chinese Medicine; Beijing Friendship... and other collaboratorsRecruiting
-
National Cancer Institute (NCI)TerminatedMetaplasia | Dysplasia | Pulmonary Precancerous ConditionUnited States
-
National Cancer Institute (NCI)CompletedNeoplasms | Precancerous ConditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Completed
-
Emory UniversityNational Institutes of Health (NIH)CompletedPrecancerous ConditionsUnited States
-
Renmin Hospital of Wuhan UniversityCompleted
-
All India Institute of Medical Sciences, New DelhiCompletedPrecancerous ConditionsIndia
-
City of Hope Medical CenterNational Cancer Institute (NCI)Completed
-
Northwestern UniversityNational Cancer Institute (NCI)CompletedPrecancerous ConditionUnited States
Clinical Trials on laboratory biomarker analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States